Author

Maki Komamine

Observed names: Komamine, Maki, Maki KOMAMINE

Institution: Pharmaceuticals and Medical Devices Agency

Observed institutions: Kyoto University, Pharmaceuticals and Medical Devices Agency

ORCID: 0000-0002-8390-0922

Observed ORCID: 0000-0002-8390-0922

OpenAlex ID: A5041026317

PMDA Perspective on RWD / RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage

2024 · Kazuhiro Kajiyama, Maki Komamine, et al. · Pharmacoepidemiology and Drug Safety · 15

Cardiovascular risks associated with dipeptidyl peptidase‐4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study

2019 · Maki Komamine, Kazuhiro Kajiyama, et al. · Pharmacoepidemiology and Drug Safety · 13

Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan

2024 · Haruka Shida, Maki Komamine, et al. · PLoS ONE · 5

Dealing with missing data in laboratory test results used as a baseline covariate: results of multi-hospital cohort studies utilizing a database system contributing to MID-NET® in Japan

2023 · Maki Komamine, Yoshiaki Fujimura, et al. · BMC Medical Informatics and Decision Making · 5

Increased risk of hypocalcemia with decreased kidney function in patients prescribed bisphosphonates based on real-world data from the MID-NET® in Japan: a new-user cohort study

2024 · Tomoaki Hasegawa, Maki Komamine, et al. · BMC Nephrology · 4

Characteristics of hospital differences in missing of clinical laboratory test results in a multi-hospital observational database contributing to MID-NET® in Japan

2021 · Maki Komamine, Yoshiaki Fujimura, et al. · BMC Medical Informatics and Decision Making · 4

1．The Achievements and Future Directions of MIHARI Project

2015 · Chieko ISHIGURO, Yoshinori TAKEUCHI, et al. · Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku · 3

Safety Comparison of Risk of Liver Dysfunction between Generic and Brand Statin Drugs Marketed in Japan: A Cohort Study Using MID-NET®

2025 · Hotaka Maruyama, Yuki Kinoshita, et al. · Therapeutic Innovation & Regulatory Science · 1

Risk of Thrombocytopenia by SSRIs or SNRIs in Patients With Depression Based on MID ‐ NET : A Cohort Study in Japan

2025 · Yusuke Okada, Kazuhiro Kajiyama, et al. · Clinical and Translational Science · 1

Characterization of MID-NET® Data for Appropriate Drug Safety Assessment： Lessons Learned from Studies Investigating Incidence of Decreased Liver Function in Patients Prescribed Drugs for Pulmonary Arterial Hypertension and Examining Real World Utilization of Biosimilars

2022 · Maki KOMAMINE, Tomoaki HASEGAWA, et al. · Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku

Works count: 17

Citation count: 51

H-index: 4

I10-index: 2